SGLT2 inhibitors such as Dapagliflozin (sodium-glucose co-transporter 2-inhibitor) can increase the hematocrit and hemoglobin levels, suggesting potential use to either correct or prevent anemia in HF patients [64]. Here, SLC5A2 is linked to anemia (phenotype).